Top

Journal of Ovarian Research

Published in:

Open Access 01-12-2017 | Research

BRCA1 expression, proliferative and apoptotic activities in ovarian epithelial inclusions

Authors: Yiying Wang, Yue Wang, Li Wei, Shuhui Hong, Miaoqing Zhao, Xi Zhang, Wenxin Zheng

Published in: Journal of Ovarian Research | Issue 1/2017

Abstract

Background

The purpose of this study was to examine proliferative and apoptotic activity in relation with BRCA1 expression in ovarian epithelial inclusions (OEIs), the putative precursor lesions of ovarian epithelial cancer (OEC).

Methods

Benign ovaries from 95 patients were examined. Dual immunohistochemical staining for both BRCA1 and MIB-1 were performed to examine the relationship between BRCA1 and MIB-1 in OEI cells. Apoptotic activity was assessed on the parallel tissue sections by using TUNEL assay. Patients’ age, menstrual phase and menopausal status were analyzed.

Results

OEIs were present in the ovaries of 53% of the patients. OEIs were less frequently found in premenopausal (45%) than postmenopausal women (58%). BRCA1 and MIB-1 were found in 27 and 47% of the OEI-containing ovaries, respectively. All BRCA1 positive OEI cells are MIB-1 positive with dual staining method, although overall the percentage of positive cells was small. No significant difference was found for BRCA1 and MIB-1 expression in OEIs between menopausal status and menstrual phases. Apoptosis containing OEIs were seen in 70% of the ovaries. Compared to OEIs in proliferative menstrual phase and premenopausal status, significantly more apoptosis was found in OEIs from secretory phase and postmenopausal women. A small fraction of the epithelial cells within OEIs are proliferating or dying.

Conclusions

Low estrogen and/or high progesterone levels may promote OEI cell turnover via induction of apoptosis. Imbalance between cell proliferation and death within OEIs under influence of hormones may play a role in the ovarian epithelial tumorigenesis.

Miki Y, Swensen J, Shattuck-Eidens D, Futreal P, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Borgden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow P, Norris F, Helvering L, Morrison P, Roseteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71.CrossRefPubMed

Westhoff C. Ovarian cancer. Annu Rev Public Health. 1996;17:85–96.CrossRefPubMed

Zheng W, Lu J, Luo F, Zheng Y, Feng Y-J, Felix JC, Lauchlan SC, Pike MC. Ovarian epithelial tumor growth promotion by FSH and inhibition of the effect by LH. Gynecol Oncol. 2000;76:80–8.CrossRefPubMed

Fathalla MF. Increased ovulation—a factor in ovarian neoplasia? Lancet. 1971;716:163–5.CrossRef

Godwin AK, Testa JR, Handel LM, Liu Z, Vanderveer LA, Tracey PA, Hamilton TC. Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. J Natl Cancer Inst. 1992;84:592–601.CrossRefPubMed

Pengetnze Y, Steed M, Roby KF, Terranova PF, Taylor CC. Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line. Biochem Biophys Res Commun. 2003;309:377–83.CrossRefPubMed

McCloskey CW, Goldberg RL, Carter LE, Gamwell LF, Al-Hujaily EM, Collins O, MacDonald EA, Garson K, Daneshmand M, Carmona E, Vanderhyden BC. A new spontaneously transformed syngeneic model of high-grade serous ovarian cancer with a tumor-initiating cell population. Front Oncol. 2014;4:53.CrossRefPubMedPubMedCentral

Pike MC. Age-related factors in cancers of the breast, ovary, and endometrium. J Chronic Dis. 1987;40:59S–69S.CrossRefPubMed

Scully RE. Pathology of ovarian cancer precursors. J Cell Biochem. 1995;23:208S–18S.CrossRef

10.

Mittal KR, Zeleniuch-Jacquotte A, Cooper JL, Demopoulos RI. Contralateral ovary in unilateral ovarian carcinoma: a search for preneoplastic lesions. Int J Gynecol Pathol. 1993;12:59–63.CrossRefPubMed

11.

Esselen KM, Terry KL, Samuel A, Elias KM, Davis M, Welch WR, Muto MG, Ng SW, Berkowitz RS. Endosalpingiosis: more than just an incidental finding at the time of gynecologic surgery? Gynecol Oncol. 2016;142:255–60.CrossRefPubMed

12.

Westhoff C, Murphy P, Heller D, Halim A. Is ovarian cancer associated with an increased frequency of germinal inclusion cysts. Am J Epidemiol. 1993;138:90–3.CrossRefPubMed

13.

Tresserra F, Grases PJ, Labastida R, Ubeda A. Histological features of the contralateral ovary in patients with unilateral ovarian cancer: a case control study. Gynecol Oncol. 1998;71:437–41.CrossRefPubMed

14.

Sherman ME, Lee JS, Burks RT, Struewing JP, Kurman RJ, Hartge P. Histopathologic features of ovaries at increased risk for carcinoma. A case-control analysis. Int J Gynecol Pathol. 1999;18:151–7.CrossRefPubMed

15.

Salazar H, Godwin AK, Daly MB, Laub PB, Hogan WM, Rosenblum N, Boente MP, Lynch HT, Hamilton TC. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies [see comments]. J Natl Cancer Inst. 1996;88:1810–20.CrossRefPubMed

16.

Werness BA, Afify AM, Bielat KL, Eltabbakh GH, Piver MS, Paterson JM. Altered surface and cyst epithelium of ovaries removed prophylactically from women with a fmaily history of ovarian cancer. Hum Pathol. 1999;30:151–7.CrossRefPubMed

17.

Li J, Abushahin N, Pang S, Xiang L, Chambers SK, Fadare O, Kong B, Zheng W. Tubal origin of ‘ovarian’ low-grade serous carcinoma. Mod Pathol. 2011;24:1488–99.CrossRefPubMed

18.

Crum CP. Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol Oncol. 2009;3:165–70.CrossRefPubMedPubMedCentral

19.

Zhang W, Wei L, Li L, Yang B, Kong B, Yao G, Zheng W. Ovarian serous carcinogenesis from tubal secretory cells. Histol Histopathol. 2015;30:1295–302.PubMed

20.

Chen C, Li J, Yao G, Chambers SK, Zheng W. Tubal origin of ovarian low-grade serous carcinoma. Am J Clin Exp Obstet Gynecol. 2013;1:13–36.PubMedPubMedCentral

21.

Esselen KM, Ng SK, Hua Y, White M, Jimenez CA, Welch WR, Drapkin R, Berkowitz RS, Ng SW. Endosalpingiosis as it relates to tubal, ovarian and serous neoplastic tissues: an immunohistochemical study of tubal and Mullerian antigens. Gynecol Oncol. 2014;132:316–21.CrossRefPubMed

22.

Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human of human cancer. Cancer Res. 1990;50:7415–21.PubMed

23.

Primas H, Kroiss R, Kalteis K, Rappaport C, Muhr D, Primas C, Kubista E, Horvat R, Oefner P, Singer C, Wagner, The Austrian Hereditary B and Ovarian Cancer Group T. Impact of lifestyle factors on preneoplastic changes in prophylactic oophorectomies of BRCA mutation carriers. Eur J Cancer Prev. 2012;21:199–204.PubMed

24.

Durant ST, Nickoloff JA. Good timing in the cell cycle for precise DNA repair by BRCA1. Cell Cycle. 2005;4:1216–22.CrossRefPubMed

25.

Zheng W, Luo F, Lu J, Baltayan A, Press M, Zhang ZF, Pike MC. Reduction of BRCA1 expression in sporadic ovarian cancer. Gynecol Oncol. 2000;76:294–300.CrossRefPubMed

26.

Gruessner C, Gruessner A, Glaser K, Abushahin N, Laughren C, Zheng W, Chambers SK. Biomarkers and endosalpingiosis in the ovarian and tubal microenvironment of women at high-risk for pelvic serous carcinoma. Am J Cancer Res. 2014;4:61–72.PubMedPubMedCentral

27.

Key G, Petersen JL, Becker MH, Duchrow M, Schluter C, Askaa J, Gerdes J. New antiserum against Ki-67 antigen suitable for double immunostaining of paraffin wax sections. J Clin Pathol. 1993;46:1080–4.CrossRefPubMedPubMedCentral

28.

Agthoven TV, Timmermans M, Foekens JA, Dorssers LCJ, Henzen-Logmans SC. Differential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry. Am J Pathol. 1994;144:1238–46.PubMedPubMedCentral

29.

Wilson CA, Ramos L, Villasenor R, Anders K, Press MF, Clarke K, Karlan B, Chen JJ, Scully R, Livingston D, Zuch RH, Kanter MH, Cohen S, Calzone FJ, Slamon DJ. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet. 1999;21:236–40.CrossRefPubMed

30.

Amezcua CA, Lu JJ, Stanczyk FZ, Zheng W. Apoptosis may be an early event of progestin therapy for endometrial hyperplasia. Gynecol Oncol. 2000;79:169–76.CrossRefPubMed

31.

Cai KQ, Klein-Szanto A, Karthik D, Edelson M, Daly MB, Ozols RF, Lynch HT, Godwin AK, Xu XX. Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutations. Gynecol Oncol. 2006;103:719–28.CrossRefPubMed

32.

Tok EC, Ertunc D, Tataroglu C, Yazici G, Kanat H, Dilek S. Clinicopathologic study of the putative precursor lesions of epithelial ovarian cancer in low-risk women. Int J Gynecol Cancer. 2006;16:501–6.CrossRefPubMed

33.

Clarke RB, Howell A, Potten CS, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res. 1997;57:4987–91.PubMed

34.

Pike MC, Spicer DV. Hormonal contraception and chemoprevention of female cancers. Endocr Relat Cancer. 2000;7:73–83.CrossRefPubMed

35.

Zhou H, Luo M, Schönthal AH, Pike MC, Stallcup MR, Blumenthal M, Zheng W, Dubeau L. Effective of Reproductive hormones on ovarian epithelial tumors: I. Effect on cell cycle activity. Cancer Biol Ther. 2002;1:300–6.CrossRefPubMed

36.

Phillips KW, Goldsworthy SM, Bennett LM, Brownlee HA, Wiseman RW, Davis BJ. Brca1 is expressed independently of hormonal stimulation in the mouse ovary. Lab Investig. 1997;76:419–25.PubMed

37.

Somasundaram K. Breast cancer gene 1 (BRCA1): role in cell cycle regulation and DNA repair—perhaps through transcription. J Cell Biochem. 2003;88:1084–91.CrossRefPubMed

38.

Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin G-Y, Abel KJ, Weber BL, Chodosh LA. The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat Genet. 1995;11:17–26.CrossRefPubMed

39.

Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T, Livingston D. M. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell. 1997;88:265–75.CrossRefPubMed

40.

Thomas JE, Smith M, Tonkinson JL, Rubinfeld B, Polakis P. Induction of phosphorylation on BRCA1 during the cell cycle and after DNA damage. Cell Growth Differ. 1997;8:801–9.PubMed

Title: BRCA1 expression, proliferative and apoptotic activities in ovarian epithelial inclusions
Authors: Yiying Wang
Yue Wang
Li Wei
Shuhui Hong
Miaoqing Zhao
Xi Zhang
Wenxin Zheng
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Journal of Ovarian Research / Issue 1/2017
Electronic ISSN: 1757-2215
DOI: https://doi.org/10.1186/s13048-017-0307-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

BRCA1 expression, proliferative and apoptotic activities in ovarian epithelial inclusions

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

The value of DCE-MRI in assessing histopathological and molecular biological features in induced rat epithelial ovarian carcinomas

Optimal FSH usage in revascularization of allotransplanted ovarian tissue in mice

HBXIP overexpression is correlated with the clinical features and survival outcome of ovarian cancer

What we learned from extended culture of ‘rejected’ day-3 cleavage stage embryos: a prospective cohort study

Follicular Fluid redox involvement for ovarian follicle growth

Is the hypothesis of preimplantation genetic screening (PGS) still supportable? A review